Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Tuesday.

Several other brokerages have also commented on TEVA. Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, November 27th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $21.00 target price (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 31st. BTIG Research upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, September 11th. Finally, Morgan Stanley set a $15.00 target price on Teva Pharmaceutical Industries and gave the company an “underweight” rating in a research report on Thursday, October 5th. Seven equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $21.65.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.01 during mid-day trading on Tuesday, hitting $15.06. The stock had a trading volume of 10,220,158 shares, compared to its average volume of 15,647,037. The firm has a market capitalization of $15,500.00, a PE ratio of 3.52 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.31.

Hedge funds have recently bought and sold shares of the company. Flow Traders U.S. LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $105,000. Sharkey Howes & Javer increased its position in shares of Teva Pharmaceutical Industries by 21.7% during the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock valued at $101,000 after acquiring an additional 358 shares during the last quarter. Hudock Capital Group LLC increased its position in shares of Teva Pharmaceutical Industries by 37.6% during the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock valued at $103,000 after acquiring an additional 564 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in shares of Teva Pharmaceutical Industries by 3.1% during the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock valued at $107,000 after acquiring an additional 64 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its position in shares of Teva Pharmaceutical Industries by 1,127.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 2,210 shares of the company’s stock valued at $118,000 after acquiring an additional 2,030 shares during the last quarter. Institutional investors own 52.05% of the company’s stock.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/teva-pharmaceutical-industries-teva-stock-rating-upgraded-by-valuengine.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.